AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31230964
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula (HFNC) (45 L/min, FIO2 100%)
Trial: 31230964
Drug: High-Flow Face
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Face Mask (HFFM) (15 L/min)
Trial: 15315998
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy and exercise training (n = 46)
Trial: 30810638
Drug: GTP (periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTP (periodontal and peri-implant maintenance therapy)
Trial: 10492157
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg daily for 2 days)
Trial: 10492157
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg daily for 21 days)
Trial: 6752878
Drug: Pirprofen 200
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirprofen 200 mg four times a day
Trial: 6752878
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 900 mg four times a day
Trial: 29929495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (one counseling session administered by a nurse)
Trial: 23327030
Drug: bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine + fentanyl (7.5 mg of 0.5% bupivacaine + 15 microg fentanyl intrathecally)
Trial: 23327030
Drug: levobupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine + fentanyl (7.5 mg of 0.5% levobupivacaine + 15 microg fentanyl intrathecally)
Trial: 16258155
Drug: Real-time polymerase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time polymerase chain reaction (PCR) assay targeting 16S rDNA, limit of detection: 40, 50, or 2000 CFU/ml for E. coli, group B Streptococcus, and Listeria monocytogenes respectively, sample preparation and PCR duration less than 4 hours.
Trial: 9951493
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TA) 75 mg/kg per day divided into 3 doses
Trial: 9951493
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 0.75 mg/kg per day divided into 2 doses
Trial: 7591596
Drug: Doxazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (4 mg/day) for 72 weeks
Trial: 7591596
Drug: Prazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (4 mg/day) for 24 weeks
Trial: 6246006
Drug: Mecillinam alone
RxNorm normalized name: mecillinam
DrugBank: Amdinocillin (DB01163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mecillinam alone or in combination with ampicillin
Trial: 6246006
Drug: Mecillinam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecillinam (5 mg/kg intravenously every six hours)
Trial: 6246006
Drug: Mecillinam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecillinam (10 mg/kg intravenously every six hours)
Trial: 6246006
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (mecillinam and ampicillin)
Trial: 31074244
Drug: Nivolumab (PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (PD-1 inhibitor) administered every second week until disease progression
Trial: 31467059
Drug: Nivolumab (PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (PD-1 inhibitor)
Trial: 27125883
Drug: Mixed fibre
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed fibre (5 g b.d. for 4 weeks)
Trial: 27125883
Drug: Psyllium (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (5 g b.d. for 4 weeks)
Trial: 15531619
Drug: Airflow via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Airflow via sponge-tipped oxygen catheter at a rate of 115 ml kg(‐1) min(‐1) for 6 hours
Trial: 12953342
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg bid for 3 days
Trial: 12953342
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg qid
Trial: 10971231
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and metronidazole 500 mg b.d. (PCM)
Trial: 10971231
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg b.d., amoxycillin 1000 mg b.d., and clarithromycin 500 mg b.d. (PAC)
Trial: 9011466
Drug: 3 MU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU interferon-alpha2b every two days for another six months (group A, total dose: 410 MU)
Trial: 9011466
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of interferon-alpha2b (6 MU every two days for three months, followed by 10 MU every two days for three months) (group B, total dose: 870 MU)
Trial: 9011466
Drug: 3 MU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU interferon-alpha2b every two days for three months (initial treatment)
Trial: 30696903
Drug: Dihydroartemisinin-piperaquine with
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine with higher dosage and extended schedule (four monthly doses)
Trial: 30696903
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage of dihydroartemisinin-piperaquine
Trial: 24099152
Drug: Moxonidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.6 mg/day
Trial: 19367282
Drug: Lomeguatrib 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomeguatrib 40 mg, b.i.d. for 10 days with temozolomide 75 mg m(‐2) on days 1‐5
Trial: 19367282
Drug: Lomeguatrib extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomeguatrib extended dosing
Trial: 15823785
Drug: Imaginative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaginative and hypnotic suggestions
Trial: 15823785
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered after suggestions)
Trial: 12516678
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral-B 35)
Trial: 9595919
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 micrograms/day for three weeks with MAP 10 mg orally for 10 days
Trial: 678495
Drug: 3.0% levamisole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0% levamisole solutions
Trial: 678495
Drug: 3.0% mebendazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0% mebendazole suspensions
Trial: 25158710
Drug: High-dose-rate brachytherapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate brachytherapy (2 × 6 Gy administered in two fractions: first within 4 hours after surgery and second within 24 hours)
Trial: 25158710
Drug: High-dose-rate brachytherapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate brachytherapy
Trial: 22067244
Drug: Control Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Condition (CC) - 5 minutes of passive rest
Trial: 15381932
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg m(‐2) irinotecan as a 90‐min i.v. infusion q3 weeks (Arm A)
Trial: 15381932
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg m(‐2) irinotecan as a 90‐min i.v. infusion weekly x 4 weeks q6 weeks (Arm B)
Trial: 15381932
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg m(‐2) irinotecan as a 90‐min i.v. infusion q2 weeks (Arm C)
Trial: 15381932
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg m(‐2) day(‐1) irinotecan as a 14‐day continuous infusion q3 weeks (Arm D)
Trial: 11118782
Drug: Systematic education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic education using a self‐conducted, interactive Kodak Photo‐CD program plus personal drug information and non‐commercial drug leaflets.
Trial: 9829706
Drug: DFMO 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO 0.5 g/m2/day
Trial: 2687688
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg every six hours)
Trial: 31904995
Drug: Energy-dense nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-dense nutrition (1.5 kcal/ml)
Trial: 30346225
Drug: Routine enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine enteral nutrition (1.0 kcal/ml)
Trial: 30513266
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cleansed adjacent to injection site)
Trial: 27670267
Drug: Minocycline 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 3 mg/mL plus EDTA 30 mg/mL (M-EDTA)
Trial: 27670267
Drug: Heparin 1000
RxNorm normalized name: HEPARIN 10000UNIT/ML CARPUJECT 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 1000 IU/mL (H)
Trial: 26370664
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives prescribed to the control group with follow-up visit advised.
Trial: 18380203
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% aluminum chloride (AC)
Trial: 9075480
Drug: p24-VLP (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p24-VLP (highest dose)
Trial: 8396320
Drug: Oral acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acyclovir, 800 mg four times daily
Trial: 8396320
Drug: Oral acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acyclovir, 800 mg four times daily + IVIG, 300 mg/kg every 2 weeks for six doses
Trial: 11280632
Drug: Intracatheter nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracatheter nitroglycerin (NTG) infusion at 0.1 mcg x kg x min in 5% dextrose
Trial: 29337906
Drug: Specific collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific collagen peptides (SCP) 5 g daily for 12 months
Trial: 24641790
Drug: QiShenYiQi dripping
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QiShenYiQi dripping pills, Tongxinluo placebo and routine medication
Trial: 24641790
Drug: Tongxinluo capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo capsules, QiShenYiQi placebo and routine medication
Trial: 22607134
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (prednisone, azathioprine, and NAC)
Trial: 7475138
Drug: Acadesine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acadesine (0.1 mg/kg per minute intravenous infusion over 7 hours, 5 micrograms/ml in cardioplegic solution)
Trial: 28138133
Drug: Baseline thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline thyroid hormones
Trial: 19121589
Drug: Oral anti-vitamin-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-vitamin-K agents (AVK)
Trial: 19121589
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) in patients with cancer
Trial: 19121589
Drug: Oral anti-vitamin-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-vitamin-K agents (AVK) in patients with cancer
Trial: 17966026
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg preoperatively and then twice daily)
Trial: 11465636
Drug: Fluoxetine (n=27)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n=27)
Trial: 9220235
Drug: 0.15% ganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ganciclovir gel
Trial: 9220235
Drug: 0.05% ganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% ganciclovir gel
Trial: 8285927
Drug: Nifedipine 60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 60 mg/d
Trial: 2821790
Drug: Bromodeoxyuridine (BUdR)
RxNorm normalized name: Bromodeoxyuridine
DrugBank: Broxuridine (DB12028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromodeoxyuridine (BUdR) or iododeoxyuridine (IUdR) during high-dose brain irradiation (total radiation dose 65-70 Gy)
Trial: 2821790
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who completed planned treatment (48 patients)
Trial: 2821790
Drug: BUdR versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUdR versus IUdR, 12-h versus 24-h infusion schedule, degree of surgical resection, or sex
Trial: 30902613
Drug: Alectinib, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib, 600 mg twice daily
Trial: 30902613
Drug: Crizotinib, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib, 250 mg
Trial: 25457735
Drug: Iodixanol 270
RxNorm normalized name: IODIXANOL 270mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol 270 (270 mg I/mL), scanned using low tube voltage of 80 kVp, reconstructed with iterative reconstruction techniques (IRT)
Trial: 25457735
Drug: Iopromide 370
RxNorm normalized name: IOPROMIDE 370mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide 370 (370 mg I/mL), scanned using 100 kVp, reconstructed with filtered back projection
Trial: 22000927
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of PYY(3-36) and GLP-1(7-36 amide)
Trial: 19891258
Drug: GaAIAS (780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 25 J/cm2.
Trial: 19891258
Drug: GaAIAS (780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 60 J/cm2.
Trial: 19891258
Drug: GaAIAS (780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 105 J/cm2.
Trial: 16489525
Drug: Capsaicin infusion
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin infusion (40 microg/ml, 2.5 ml/min for 60 minutes)
Trial: 15486846
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (VAQTA; Merck), administered at weeks 0 and 24
Trial: 6365849
Drug: Riboflavin supplement
RxNorm normalized name: Riboflavin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin supplement (15 mg)
Trial: 17275926
Drug: Sucralfate (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1g solution, swished and swallowed four times daily for 7 days)
Trial: 17275926
Drug: Lactulose (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (1g solution, swished and swallowed four times daily for 7 days)
Trial: 10344012
Drug: Antioxidant therapy;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy; specific details on dosage and duration not available
Trial: 7562419
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) 10 U/kg i.v. bolus dose
Trial: 7562419
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) 100 U/kg i.v. bolus dose
Trial: 7562419
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) 500 U/kg i.v. bolus dose
Trial: 30205241
Drug: Dietary sodium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary sodium reduction to <1500 mg daily counseling
Trial: 18551008
Drug: Heart rate
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate controlled 12 week exercise program (arm-cycling at target lactate concentrations of 2.0 +/- 0.5 mmol/l)
Trial: 15786889
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) with TST screening
Trial: 15786889
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) without TST screening
Trial: 31714586
Drug: MK-2206 200
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 200 mg weekly (initial dose), reduced to 135 mg due to toxicity
Trial: 31270967
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron administration
Trial: 27392481
Drug: CM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM plus WM therapy (Reduning Injection or Xiyanping Injection)
Trial: 27392481
Drug: WM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WM therapy alone
Trial: 22297674
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg elemental calcium diet
Trial: 22297674
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg elemental calcium diet
Trial: 11346139
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate-based triple therapy (RAM group)
Trial: 11346139
Drug: Omeprazole-based triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-based triple therapy (OAM group)
Trial: 15258452
Drug: 3% ascorbic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% ascorbic acid cream
Trial: 9076466
Drug: Pre-operative blood
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative blood haemoglobin concentration in the range of 100-129 g/l
Trial: 9076466
Drug: Adjusted for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted for impaired health status and age > or = 75 years, fluid absorption > or = 500 ml, and blood loss > or = 275 ml
Trial: 8419003
Drug: Indobufen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (100 mg b.i.d.)
Trial: 19364302
Drug: Vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 100 mg once daily
Trial: 15464786
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU)
Trial: 31937352
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day krill oil
Trial: 16500491
Drug: ivMCE (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivMCE (intravenous myocardial contrast echocardiography)
Trial: 12404073
Drug: Heroin (491
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin (491 mg average daily dose, n=17)
Trial: 12404073
Drug: Morphine (597
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (597 mg average daily dose, n=16)
Trial: 10846637
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (drug intake every day for the whole experimental period)
Trial: 9160923
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg twice daily for 2 weeks
Trial: 24358760
Drug: Improved central
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved central venous catheter indwelling of intraperitoneal drainage, irrigation, cavity injection, combined with systemic comprehensive treatment
Trial: 28038680
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo